Plasmid DNA Development

As part of our integrated Pharmaceutical Development & Manufacturing framework, we provide specialized capabilities within Drug Substance Development, with a focused offering under Gene Therapy Vector Development. Our plasmid DNA development service concentrates on the R&D phase—design, engineering, and characterization—to enable reliable, phase-appropriate advancement of non-viral nucleic payloads.

Design & Strategy Service

We begin with target definition and use-case mapping to select backbone architecture, promoter/enhancer schemes, polyadenylation elements, origins of replication, selection systems, and modular cloning strategies. We evaluate payload size tolerance, copy-number goals, and replication control to minimize sequence stress. Decision records capture trade-offs among expression strength, payload compactness, and downstream delivery compatibility.

Sequence Optimization & Biosafety Service

Our sequence optimization aligns codon usage, GC balance, mRNA structure, and rare-codon frequency with the intended expression context while maintaining amino-acid fidelity where applicable. We remove extraneous CpG clusters where appropriate and screen for repeats, cryptic splice sites, and recombination-prone elements. We also provide antibiotic-free selection strategies (e.g., operator–repressor or auxotrophy-based systems) to reduce reliance on traditional markers. Bioinformatic assessments include in-silico restriction mapping, off-target homology checks, and motif audits.

Plasmid Construct Engineering Service

Using modular cloning, we construct single-cassette or multi-cistronic plasmids with standardized linkers, and interchangeable promoter modules. We emphasize assembly routes that are robust to payload complexity and that scale predictably across variants. We also support minicircle-ready designs and antibiotic-free backbone conversions during this stage when aligned with program strategy.

Analytical Characterization Service

Our R&D analytics establish identity, purity, and key performance indicators suited to pDNA. Methods typically include:

• Sequence Identity: Full-length sequence confirmation with variant analysis.
• Topology Profiling: Supercoiled, open-circular, and linear fractions by agarose or capillary methods.
• Impurity Panels: Host nucleic acid residuals (qualitative R&D checks), RNA carryover, residual enzymes (method development), and residual solvents (fit-for-purpose R&D assessment).
• Physicochemical Attributes: A260/A280/A230 ratios, hydrodynamic size, and aggregation propensity screens.
• Functional Readouts: Cell-based expression screens that compare promoter activity tiers and transcriptional architectures under standardized conditions to de-risk sequence choices.